APAC Blood Testing Market

APAC Blood Testing Market Size (2022 to 2027)

The blood testing market size in APAC is expected to grow from USD 10.34 billion in 2022 to USD 12.19 billion by 2027, growing at a CAGR of 3.35% during the forecast period.

The blood testing market involves blood sampling and collection activities. Blood testing helps doctors to identify and detect any underlying issues in the body through blood tests. HIV/AIDS, Diabetes, Cancers, and any other Heart issues can be detected through blood tests.

Key factors contributing to the growth of this market contain the growing number of chronic cases and the high price of treatment, rise in the occurrence of infectious diseases, speedily increasing aging population, boost in product approvals and launches, increase in demand for quick diagnostic techniques, and high commonness of bloodstream infections.

The Asia Pacific has been reported as the fastest-growing market for Blood testing. The dense population in this region drives market growth. In addition, the demand for frequent check-ups for increasing diseases such as Diabetes, Cancers, Liver Diseases, and Cardiovascular disorders increases market size. The government schemes in this region on creating awareness of medications, blood donation drives, and personalizing medications depending on body type are a boom to market.

During the forthcoming years, Asia-Pacific has been recognized as the fastest-growing region. Blood is a vital component of the body and is used routinely in a wide range of hospital procedures. Every year, millions of blood units are donated globally and used in necessary transplantation, cancer therapies, accident victims, and patients undergoing other surgeries.

Still, factors such as a lack of technically skilled professionals are restraining this market's growth.

This research report on the Asia Pacific Blood Testing Market has been segmented and sub-segmented into the following categories:

By Type:

• Complete Blood Count
  • Red Blood Cells
  • White Blood Cells
  • Hemoglobin
  • Haematocrit
  • Platelets
• Blood Chemistry Tests
  • Electrolytes
  • Blood Glucose
  • Calcium
  • Test for Kidney Function
• Blood Enzymes Tests
  • Troponin
  • Creatine Kinase
• Blood Clotting Tests
  • Prothrombin time
  • Activated Partial Thromboplastin time
  • Blood Coagulation

By Disease:

• Anemia
• Infection
• Leukemia
• Hypokalemia
• Kidney Disorders
• Heart Attack
• Coronary Heart Disease

By Method:

• Manual Blood Culture Testing
• Automated Blood Culture Testing
• Automated Blood Culture System
• Blood Culture Instruments

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Based on the region, China and India are the fastest-growing markets in the Asia-Pacific region. China and Japan are highly populated regions, and the spread of infectious diseases is on the rise yearly. The corresponding government makes regulations and strict guidelines to regulate and prevent infections. 47% of the Asia Pacific population is reported to donate blood in recent years. As the hike is seen in blood donation and drives, blood collection, and sampling are also observed. India holds the largest share of blood banks, helping hospitals and clinics provide blood in emergency cases. Growing major vital players across the Asia Pacific region also increases the market level.

KEY MARKET PLAYERS:

Companies dominating the Asia Pacific blood testing market profiled in the report are Bio-Rad Laboratories Inc. (U.S.), Siemens Healthcare (Germany), Grifols (Spain), Nanosphere Inc. (U.S.), BioMérieux (France), Dickinson and Company (U.S.), Ortho Clinical Diagnostics Inc. (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Bruker Corporation (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.) and Beckman Coulter (U.S.).